First new treatment of its kind in over 20 years.
Currently only approved for men and transgender women; future trials expected.
For granulomatosis with microscopic polyangiitis in children.
Now approved for risk reductions in patients with type 2 diabetes mellitus.
Monoclonal antibody for autoimmune and neurodegenerative disorders.
Now approved in 7mg and 14 mg tablets.
Derived from cultured adult bone marrow-derived mesenchymal stem cells that have undergone temporary genetic modification.
Monoclonal antibody shows potential for lupus nephritis treatment.
Combination therapy for advance endometrial carcinoma.
NHE3 inhibitor administered as 50 mg oral tablets.